EGFR and non-small cell lung carcinoma: Advances in immune checkpoint inhibitors (ICIs) targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, such as pembrolizumab, improved survival compared with platinum-based chemotherapy in advanced NSCLC patients with PD-L1 expression of at least 50% and without EGFR mutation or anaplastic lymphoma kinase gene translocation [6].